Domestic selling price and medical insurance reimbursement details of lorlatinib in 2024

Lorlatinib (Lorlatinib, also known as lorlatinib), as a leader in ALK inhibitors, has become the first choice for treatment of many patients with non-small cell lung cancer. It is specifically targeted at ALK-positive locally advanced or metastatic non-small cell lung cancer, bringing new treatment hope to patients. Its unique mechanism of action can effectively inhibit the growth and spread of cancer cells, helping patients control their disease and improve their quality of life.

Talking aboutThe price of lorlatinib in China in 2024. According to public information, the price of lorlatinib in domestic hospitals is approximately more than 10,000 yuan per box (100mg/30 tablets). This price is based on current market conditions and drug pricing policies. The actual price may fluctuate depending on the region, hospital and drug specifications.

At the level of medical insurance reimbursement, lorlatinib has been honored to be included in the national medical insurance directory. This means that patients who meet the conditions for medical insurance reimbursement will have the opportunity to receive partial or full reimbursement of the cost of lorlatinib. The specific proportion and amount of medical insurance reimbursement may vary by region and policy, but in general, the implementation of medical insurance policies has greatly reduced the financial pressure on patients, allowing more patients to afford this highly effective targeted therapy.

However, medical insurance reimbursement usually has certain thresholds, and patients who do not meet the requirements must bear the costs themselves. For these patients, purchasing generic drugs overseas may be an option worth considering. Currently, the Lucius version of generic drugs is affordable and of reliable quality, providing patients with new treatment options.

In general,The domestic price of lorlatinib in 2024 will be about more than 10,000 yuan per box, and it has been included in the national medical insurance directory, providing patients with the possibility of medical insurance reimbursement. The implementation of this policy will undoubtedly bring more treatment options and financial support to patients.